ContraVir Pharmaceuticals, Inc, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced that it will present new preclinical data for its novel antiviral compound CRV431, including evidence of synergy with ContraVir's phase 2 tenofovir prodrug CMX157 against hepatitis B.

The data support ContraVir's strategy for developing a combination therapy that may provide a functional cure for hepatitis B.

The findings will be presented at a joint meeting sponsored by the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) focused on the discovery and development of novel therapeutic agents for chronic hepatitis B.